CD274 and pituitary tumor: Additionally, ICIs including PD-1/PD-L1 axis blockade may offer a promising therapeutic strategy for treating refractory pituitary tumors, and several clinical trials have been reported in a series of isolated cases (48–51), a clinical trial with 4 cases (52), and another cohort with 15 cases (53).